Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

Breast Cancer Research and Treatment

Volumn 49, Issue 2, 1998, Pages 145-154

  Solomayer, E F ^a   Diel, I J ^a   Meyberg, G C ^a   Gollan, Ch ^a   Bode, S ^a   Wallwiener, D ^a   Bastert, G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; Cathepsin D; Micrometastasis; Prognostic factor; Tumour cell detection

Indexed keywords

CATHEPSIN D; GLYCOPROTEIN;

ADULT; ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; ENZYME ASSAY; FEMALE; HUMAN; ILIAC CREST; IMMUNOCYTOCHEMISTRY; INTERPHASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

BONE MARROW; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; CATHEPSIN D; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS;

EID: 0031841087     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005965927185     Document Type: Article

References (54)

1. Lee KC: The clinical alert from the National Cancer Institute [Letter]. N Engl J Med 319: 948-949, 1988
2. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992
3. Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, Machiavelli M, Rodriquez R, Alvarez LA: Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol 11: 618-622, 1988
4. Leto G, Gebbia N, Rausa L, Tumminello FM: Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res 12: 235-240, 1992
5. Liotta LA: Tumor invasion and metastasis: Role of the extracellular matrix. Cancer Res 46: 1-7, 1986
6. Pollaren J, Stephens R, Salonen EM, Vahen A: Proteolytic mechanisms operating at the surface of invasive cells. Adv Exp Biol Med 233: 187-199, 1989
7. Tryggvason K, Höyhtyä M. Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochem Biophys Acta 907: 191-217, 1987
8. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 10: 1534-1539, 1992
9. Diel IJ, Kaufmann M, Costa SD, Holle R, Von Minckwitz G, Solomayer EF, Kaul S, Bastert G: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88: 1652-1658, 1996
10. Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet J-C, McKinna A, Powles TJ, Coombes RC: Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 295: 1093-1096, 1987
11. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP: Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 51: 2706-2709, 1991
12. Schlimok G, Funke I, Holzmann B, Göttlinger G, Schmidt G, Häuser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H, Rietmüller G: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci 84: 8672-8676, 1987
13. Untch M, Harbeck N, Eiermann W: Micrometastases in bone marrow in patients with breast cancer [letter]. Br Med J 296: 290, 1988
14. Diel IJ, Kaufmann M, Costa SD, Bastert G: Monoclonal antibodies to detect breast cancer cells. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. Lippincott, Philadelphia, 1994, pp 143-164
15. Frassica FJ, Sim FH: Pathogenesis and prognosis. In: Sim FH (ed) Diagnosis and Management of Metastatic Bone Disease. Raven, New York, 1988, 16
16. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmüller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85: 1419-1424, 1993
17. Solomayer E-F, Diel IJ, Wallwiener D, Bode S, Meyberg G, Sillem M, Gollan Ch, Kramer MD, Krainick U Bastert G: Prognostic relevance of uPA detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer 76: 812-818, 1997
18. Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353-362, 1980
19. Rochefort H, Capony F, Garcia M: Cathepsin D: a protease involved in breast cancer metastasis. Cancer Met Rev 9: 321-331, 1990
20. Maguchi S, Taniguchi N, Makita A: Elevated activity and increased mannose-6-phosphatase in the carbohydrate moiety of cathepsin D from human hepatoma. Cancer Res 48: 362-367, 1988
21. Sinadinovic J, Cvejic D, Savin S, Micic JV, Jancic-Zguricas M: Enhanced acid protease activity of lysosomes from papillary thyroid carcinoma: Cancer 63: 1179-1182, 1989
22. Clark GM: Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott/Raven, Philadelphia, New-York, 1996, pp 461-485
23. Ravdin PM: Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24: 219-226, 1993
24. Rochefort H: Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol 31: 125-130, 1992
25. Schultz DC, Bazel S, Wright LM, Tucker S, Lange MK, Tachovsky Th, Longo S, Niedbala S, Alhadeff JA: Western blotting and enzymatic activity analysis of cathepsin D in breast tissue and sera of patients with breast cancer and benign breast disease and of normal controls. Cancer Res 54: 48-54, 1994
26. Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case LD: Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198-5203, 1992
27. Spyratos F, Maudelonde T, Brouillet JP, Brunet M, Defrenne A, Andrieu C, Hacene K, Desplaces A, Rouesse J, Rochefort H: Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 2: 1115-1118, 1989
28. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen I, Khalaf S, Paolucci F, Pau B, Rasmussen BB, Rose C: Association between high concentrations of 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014, 1989
29. Joensuu H, Toikkanen S, Isola J: Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 71: 155-159, 1995
30. Johnson MD, Torri JA, Lippman ME, Dickson RB: The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 53: 873-877, 1993
31. Brouillet JP, Theillet C, Maudelonde T, Defrenne A, Simony-Lafontaine J, Sertour J, Pujol H, Jeanteur P, Rochefort H: Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer 26: 437-441, 1990
32. Foucre D, Bouchet C, Hacene K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J: Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumors. Br J Cancer 64: 926-932, 1991
33. Namer M, Ramaioli A, Fontana X, Etienne MC, Hery M, Jourlait A, Milano G, Frenay M, Francois E, Lapalus F: Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat 19: 85-93, 1991
34. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302, 1990
35. Jamshidi K, Swaim WR, Raisz G: A new trephine for closed bone marrow biopsy. Acta Haemat 64: 216, 1980
36. Bastert G, Eichler A, Kaul S: Monoclonal antibodies against breast cancer. In: Rygaard J, Brünner N, Spang-Thomsen M (eds) Immune Deficient Animals in Biomedical Research. Karger, Basel, 1987, pp 224-227
37. Werner M, Kaul S, Bastert G: Biochemical characterization of the mucin like tumor associated antigen TAG-12. J Cancer Res Clin Oncol 114: 59, 1988
38. Collett D: Modelling Survival Data in Medical Research. Chapman and Hall, London, 1994
39. Breslow N: Covariance analysis of censored survival data. Biometrics 30: 89-99, 1974
40. Riesenberg R, Oberneder R, Kriegmair M, Epp M, Bitzer U, Hofstetter A, Braun S, Riethmüller G, Pantel K: Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 99: 61-66, 1993
41. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1: 1035-1039, 1995
42. Ricoveri W, Cappelletti R: Heparan sulfate endoglycosidase and metastatic potential in murine fibrosarcoma and melanoma. Cancer Res 46: 3855-3861, 1986
43. Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H: A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 71: 2006-2012, 1993
44. Herlyn M: Human melanoma: development and progression. Cancer Met Rev 9: 101-112, 1990
45. Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg-Wilhelm F, Heiss MM: An immunohistochemical assessment of cathepsin D in gastric carcinoma. Its impact on clinical prognosis. Cancer 80: 179-187, 1997
46. Laiho M, Keski-Oja J: Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 49: 2533-2553, 1989
47. McDonnell S, Matrisian LM: Stromelysin in tumor progression and metastasis. Cancer Met Rev 9: 305-319, 1990
48. Remmele W, Sauer-Manthey J: Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch A Pathol Anat Histopathol 422: 467-473, 1993
49. Têtu B, Brisson J, Cote C, Brisson S, Potvin D, Roberge N: Prognostic significance of cathepsin D expression in nodepositive breast carcinoma: an immunohistochemical study. Int J Cancer 55: 429-435, 1993
50. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC, Osborne CK: Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467-474, 1994
51. Nadji M, Fresno M, Nassiri M, Conner G, Herrero A, Morales AR: Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum Pathol 27: 890-895, 1996
52. O'Donoghue AE, Poller DN, Bell JA, Galea MH, Elston CW, Blamey RW, Ellis IO: Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat 33: 137-145, 1995
53. Pyke C, Graem N, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brunner N, Dano K: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915, 1993
54. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS:The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866, 1994